PaperComparison of the nucleotide and deduced amino acid sequences of the structural protein genes of the yellow fever 17DD vaccine strain from Senegal with those of other yellow fever vaccine viruses
References (14)
- et al.
Comparison of the nucleotide and deduced amino acid sequence of the envelope protein genes of wild-type French viscerotropic strain of yellow fever virus and the live vaccine strain, French Neurotropic vaccine, derived from it
Virology
(1993) - et al.
Heterogeneity in envelope protein sequences and N-linked glycosylation among yellow fever vaccine strains
Virology
(1992) - et al.
Monoclonal antibodies that distinguish between wild and vaccine strains of yellow fever virus by neutralization, haemagglutination inhibition and immune precipitation of the virus envelope
Virology
(1983) - et al.
Flaviviridae
Intervirology
(1985) - et al.
Antigenic relationships between flaviviruses as determined by cross-neutralization tests between flaviviruses with polyclonal antisera
J. Gen. Virol.
(1989) Yellow fever vaccines
Bull. Inst. Pasteur
(1987)- et al.
Nucleotide sequence of yellow fever virus: Implications for flavivirus gene expression and evolution
Science
(1985)
Cited by (17)
Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice
2014, VirologyCitation Excerpt :Currently, substrains 17D-204, 17D-213, and 17DD are used for vaccine manufacturing. Although genetically distinct, all three substrains are immunogenic and efficacious, with amino acid substitutions likely responsible for attenuation (dos Santos et al., 1995; Jennings et al., 1993; Lang et al., 1999). A single dose of vaccine confers life-long protective immunity; therefore, a booster dose is not needed in most cases (Gotuzzo et al., 2013; Patel and Simons, 2013).
Yellow fever vaccine
2012, Vaccines: Sixth EditionComprehensive analysis of T cell epitope discovery strategies using 17DD yellow fever virus structural proteins and BALB/c (H2<sup>d</sup>) mice model
2008, VirologyCitation Excerpt :The 17D, 17D-213, and 17DD, YF strains used for human vaccination are products of multiple passages of the virulent parental Asibi virus (Galler et al., 1997). The molecular basis of the attenuation has been identified, and all the vaccine strains have been shown to differ from the wild-type virus in a few amino acids (dos Santos et al., 1995; Galler et al., 1997; Jennings et al., 1993; Post et al., 1992). The strain 17D has been successfully used worldwide for more than 65 years.
Yellow fever vaccine
2008, Vaccines